Companies

Alumni
QuickFire
Challenge Winner
At Ab Initio, we are using a proprietary directed evolution engineering technology to
Alumni
Achelois’ mission is to develop effective and nontoxic therapeutics to inhibit tumors, and
Alumni
Adicet is developing a novell cell therapy platform.
Ankasa is developing proprietary formulations of WNT stem cell activators to enable self
BioDevek is a medical device company whose mission is to transform the field of surgical
CarnaBio's goal is to develop novel methodologies to attack undruggable/ difficult targets
Cero Therapeutics is a pre-clinical biotechnology company devoted to developing next
QuickFire
Challenge Winner
Remotely control chimeric antigen receptor, or CAR, therapeutics.
Alumni
Antibody therapeutics for the immune synapse.
Alumni
QuickFire
Challenge Winner
Cyteir is revolutionizing the concept of DNA damage and repair. Conventional therapies
Alumni
Dragonfly Therapeutics develops novel first-in-class therapeutics targeted at Natural
Alumni
Fibralign Corporation is a developer of advanced biomedical devices that utilizes
Tech enabled dynamic scoliosis brace that allows real-time physician monitoring of
Alumni
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of
Alumni
HiFiBiO SAS commercializes proprietary single cell technologies for applications in drug